Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Expected to Reach $5.1 Billion by 2030

Minimally invasive glaucoma surgery (MIGS) devices market size was valued at $298.75 million in 2020, and is projected to reach $5,099.38 million by 2030, registering a CAGR of 35.0% from 2021 to 2030.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/4547

The minimally invasive glaucoma surgery (MIGS) devices are employed in the treatment of glaucoma to provide a safer and less invasive means of reducing intraocular pressure (IOP) as compared to conventional glaucoma surgery devices. MIGS devices are anticipated to become a preferred surgical modality in near future for the treatment of glaucoma as it reduces dependency on topical medications as well as gets rid of complications associated to traditional procedures. Moreover, MIGS devices are most commonly employed in combined cataract surgeries through phacoemulsification. In addition, two prime approaches of IOP reduction by MIGS involve increase in trabecular outflow through bypassing the juxtacanalicular trabecular meshwork (TM) and rise in uveoscleral outflow via suprachoroidal pathways. These two approaches are most commonly used in the treatment of glaucoma as these approaches can reduce the IOP in eyes effectively while reducing post-operative complications.

Increase in focus on developing combination surgeries for the treatment of glaucoma, high prevalence of open-angle glaucoma, and rapid rise in geriatric population are anticipated to drive the growth of the minimally invasive glaucoma surgery (MIGS) devices market. In addition, increase in the changing demographics leading to obesity, diabetes, and varied eye disorders supplement the market growth. However, dearth of skilled professionals to perform minimally invasive glaucoma surgeries efficiently and high cost of the MIGS device hamper the market. Conversely, surge in investment by manufacturers in the emerging economies and rise in initiatives to reduce the burden of glaucoma globally are anticipated to offer lucrative opportunities for market expansion.

The minimally invasive glaucoma surgery (MIGS) devices market is segmented into surgery type, target, product, end user, and region.

𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 https://www.alliedmarketresearch.com/purchase-enquiry/4547

By target, the market is divided into trabecular meshwork, suprachoroidal space, and others. The trabecular meshwork segment is anticipated to depict significant growth during the forecast period due to ineffective drug delivery witnessed in the glaucoma medication has propelled the transition of glaucoma treatment from medication to minimally invasive glaucoma surgery (MIGS) devices, thereby augmenting the market growth.

By product, the market is divided into MIGS stents, MIGS shunts, and other. The MIGS stents segment is anticipated to depict significant growth during the forecast period. Increase in demand for surgical devices in emerging countries is expected to boost the growth of these segments during the forecast period.

By end user, the market is divided into eye hospitals, ophthalmology clinics, and outpatient surgical centers. The eye hospitals segment is anticipated to depict significant growth during the forecast period and is expected to exhibit a lucrative CAGR during the forecast period. Introduction of advanced surgical devices, shorter waiting time, cost efficiency, and rise in awareness about MIGS surgery and treatment devices are expected to boost the segment growth during the forecast period.

𝐊𝐄𝐘 𝐅𝐈𝐍𝐃𝐈𝐍𝐆𝐒 𝐎𝐅 𝐓𝐇𝐄 𝐒𝐓𝐔𝐃𝐘

• By surgery type, the glaucoma in conjunction with cataract segment held the largest market share in 2020 and is expected to remain dominant during the forecast period
• By target, the trabecular meshwork segment held the largest market share in 2020 and is likely to continue dominance during the forecast period.
• By product, the MIGS shunts segment is expected to register the highest CAGR during the forecast period
• By end user, the eye hospital segment spearheaded the market in 2020 and is expected to remain dominant during the forecast period
• By region, Asia-Pacific is expected to experience minimally invasive glaucoma surgery (MIGS) devices market growth at the highest rate during the forecast period

𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:

Vaccines Market -- https://www.alliedmarketresearch.com/vaccines-market

Biopharmaceuticals Market -- https://www.alliedmarketresearch.com/biopharmaceutical-market

Contact:

David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.